Want to talk to us about biosensors?
Emerging biosensor technologies are enabling the measurement and analysis of valuable trace markers, leading to improved clinical outcomes by allowing the accurate observation of previously undetectable physiological signals.
From pharmaceutical companies using wearable sensors to generate real-time data for clinical trials, to medical device manufacturers improving diabetes management with continuous glucose measurements, healthcare is undergoing a digital revolution. Whether these large data sets are analysed at a population level to identify trends and predict outcomes, or at a patient level to assess the efficacy of a personalised therapy, the advantages are contingent on the ability to sense rich, accurate data. Biosensors provide this data; they respond to the presence of a biological analyte and convert this response into a useful signal.
Biotechnology companies, pharmaceutical manufacturers, and sensor firms are investing in research and development priorities which include: the elimination of time-consuming sample enrichment; a move from discrete tests to real-time monitors; non-invasive measurement; and, crucially, reduction to the per-test cost.
TTP works with clients to design and develop biosensors that enable the successful measurement of previously undetectable physiological signals.
The modelling phase is an area where TTP has excelled in producing unique applications to our problems. TTP engineers developed laboratory test beds that verified the modelling process and provided the ability to test theorized solutions without the need to do full-scale pilots. By narrowing down proposed solutions first by modelling and then on a test bed we could focus on a few key possibilities in our manufacturing environment, saving time and resources in this critical area.
We work at the intersection of physics, engineering and the biological sciences, creating and developing new technology for the life science industry.
Pharmaceutical companies face substantial challenges, from constraints in health spending to weakening drug pipelines. Yet opportunities exist for those bold enough to adapt, ranging from connected devices that drive adherence to generic devices at cost points previously thought impossible.
Disruptive change is rolling through the medical device industry as value-based healthcare and digitisation spread from niches to the mainstream. This is a challenging time, but it presents real opportunities for those ambitious companies prepared to reinvent themselves.
The diagnostic market is at a moment of change. New approaches, such as sequencing, are gaining traction; companion diagnostics are driving closer integration with therapy; continuous monitoring is enabling new diagnostic information; and market drivers are demanding low cost distribution of clinical quality data.
Human therapies are adapting to tackle increasingly complex immunological diseases and conditions. These therapies often rely on tightly controlled cell cultures in order to produce therapeutic drugs efficiently, such as monoclonal antibodies or culture of the patient’s own genetically-engineered cells, as part of an autologous cell therapy workflow.
Increasing numbers of people are suffering from chronic conditions. Through the creation of tiny, fully integrated real-time measurement systems, smart implants are bringing the benefits of laboratory-grade telemetry to their lives.
As with other industries, digital technology is touching every aspect of healthcare. But health is unique in its complexity, and innovation requires deep insight.
Medical imaging is required to meet the needs of advanced diagnostics and the demands of emerging markets, presenting the sector with sizeable rewards for innovation.
Surgery is a fertile area for medical device innovation with remarkable developments occurring in minimally invasive and robotic assisted techniques. The future of the operating room relies on intraoperative technologies which improve clinical and economic values as measured by procedure outcome, workflow efficiency and patient safety.